Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06335303




Registration number
NCT06335303
Ethics application status
Date submitted
22/03/2024
Date registered
28/03/2024

Titles & IDs
Public title
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Scientific title
A Randomised, Double-blind, Placebo-controlled, Dose-finding Study Evaluating Efficacy, Safety, and Tolerability of Different Oral Doses of BI 1819479 Over at Least 24 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Secondary ID [1] 0 0
2023-508395-11-00
Secondary ID [2] 0 0
1462-0004
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BI 1819479
Treatment: Drugs - Placebo matching BI 1819479

Experimental: BI 1819479 low dose treatment group -

Experimental: BI 1819479 medium dose treatment group -

Experimental: BI 1819479 high dose treatment group -

Placebo comparator: Placebo group -


Treatment: Drugs: BI 1819479
BI 1819479

Treatment: Drugs: Placebo matching BI 1819479
Placebo matching BI 1819479
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annual rate of decline in Forced Vital Capacity (FVC) [milliLiter/year]
Timepoint [1] 0 0
Up to 52 weeks
Secondary outcome [1] 0 0
Absolute change from baseline in FVC at Week 24 [in milliLiter]
Timepoint [1] 0 0
At baseline and at week 24

Eligibility
Key inclusion criteria
1. Patients =40 years old at the time of signed informed consent.
2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
3. Diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
4. On stable treatment with nintedanib or pirfenidone for at least 12 weeks or not on treatment with either nintedanib or pirfenidone for at least 12 weeks
5. Forced Vital Capacity (FVC) =45% of predicted normal.
6. Diffusion capacity of the lung for carbon monoxide (DLCO) =25% of predicted normal corrected for hemoglobin (Hb).
7. Women of childbearing potential (WOCBP) must use highly effective methods of birth control with low user dependency and additional barrier contraception for male partners (use of condom) until end of follow-up period.
8. Male trial participants with WOCBP partners must use contraception (condom) to avoid exposure via seminal fluid. Female partners of male trial participants must use highly effective methods of contraception during treatment until end of follow-up period.
Minimum age
40 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Acute exacerbation of Idiopathic Pulmonary Fibrosis (IPF) within at least 12 weeks prior to screening and/or during the screening period (investigator-determined).
2. Treated with immunosuppressive medications (other than oral corticosteroids) or prednisone >15 mg/day or equivalent for respiratory or pulmonary reasons.
3. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
4. The patient is currently enrolled in another investigational device or drug trial, or their Visit 1 occurs less than 30 days or 5 half-lives (whichever is longer) after completing a previous investigational device or drug trial or receiving other investigational treatments.
5. Patients with a significant disease or condition other than the IPF under study, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with trial procedures, or cause concern regarding the patient's ability to participate in the trial or any medical condition which could lead to a life expectancy <12 months.
6. Relevant airways obstruction (pre-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <0.7).
7. In the opinion of the Investigator, other clinically significant pulmonary abnormalities.
8. Lower respiratory tract infection requiring treatment within 4 weeks prior to Visit 1 and/or during the screening period.

Further exclusion criteria apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/09/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
21/07/2026
Actual
Sample size
Target
300
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,TAS,VIC,WA
Recruitment hospital [1] 0 0
Canberra Hospital - Garran
Recruitment hospital [2] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [3] 0 0
Launceston Respiratory & Sleep Centre - Launceston
Recruitment hospital [4] 0 0
Lung Research Victoria - Footscray
Recruitment hospital [5] 0 0
Austin Hospital - Heidelberg
Recruitment hospital [6] 0 0
Institute for Respiratory Health - Nedlands
Recruitment postcode(s) [1] 0 0
2605 - Garran
Recruitment postcode(s) [2] 0 0
2050 - Camperdown
Recruitment postcode(s) [3] 0 0
7250 - Launceston
Recruitment postcode(s) [4] 0 0
3011 - Footscray
Recruitment postcode(s) [5] 0 0
3084 - Heidelberg
Recruitment postcode(s) [6] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Michigan
Country [6] 0 0
United States of America
State/province [6] 0 0
Mississippi
Country [7] 0 0
United States of America
State/province [7] 0 0
Nevada
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
South Carolina
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
Argentina
State/province [14] 0 0
C.a.b.a
Country [15] 0 0
Argentina
State/province [15] 0 0
Caba
Country [16] 0 0
Argentina
State/province [16] 0 0
Capital Federal
Country [17] 0 0
Austria
State/province [17] 0 0
Linz
Country [18] 0 0
Austria
State/province [18] 0 0
Vienna
Country [19] 0 0
Belgium
State/province [19] 0 0
Liège
Country [20] 0 0
Brazil
State/province [20] 0 0
Barra Mansa
Country [21] 0 0
Brazil
State/province [21] 0 0
Botucatu
Country [22] 0 0
Brazil
State/province [22] 0 0
Goiania
Country [23] 0 0
Brazil
State/province [23] 0 0
Porto Alegre
Country [24] 0 0
Brazil
State/province [24] 0 0
Santo André
Country [25] 0 0
Brazil
State/province [25] 0 0
Sao Paulo
Country [26] 0 0
Brazil
State/province [26] 0 0
SJC
Country [27] 0 0
Canada
State/province [27] 0 0
Alberta
Country [28] 0 0
Canada
State/province [28] 0 0
Nova Scotia
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Canada
State/province [30] 0 0
Quebec
Country [31] 0 0
China
State/province [31] 0 0
Beijing
Country [32] 0 0
China
State/province [32] 0 0
Chengdu
Country [33] 0 0
China
State/province [33] 0 0
Nanjing
Country [34] 0 0
China
State/province [34] 0 0
Shanghai
Country [35] 0 0
China
State/province [35] 0 0
Xuzhou
Country [36] 0 0
Czechia
State/province [36] 0 0
Prague
Country [37] 0 0
Denmark
State/province [37] 0 0
København Ø
Country [38] 0 0
France
State/province [38] 0 0
Marseille
Country [39] 0 0
France
State/province [39] 0 0
Nice
Country [40] 0 0
France
State/province [40] 0 0
Rouen
Country [41] 0 0
Germany
State/province [41] 0 0
Bad Homburg
Country [42] 0 0
Germany
State/province [42] 0 0
Fulda
Country [43] 0 0
Germany
State/province [43] 0 0
Greifswald
Country [44] 0 0
Germany
State/province [44] 0 0
Hemer
Country [45] 0 0
Germany
State/province [45] 0 0
Leipzig
Country [46] 0 0
Germany
State/province [46] 0 0
München
Country [47] 0 0
Greece
State/province [47] 0 0
Ioannina
Country [48] 0 0
Greece
State/province [48] 0 0
Patras
Country [49] 0 0
Greece
State/province [49] 0 0
Voutes
Country [50] 0 0
Hungary
State/province [50] 0 0
Budapest
Country [51] 0 0
Italy
State/province [51] 0 0
Foggia
Country [52] 0 0
Italy
State/province [52] 0 0
Milano
Country [53] 0 0
Italy
State/province [53] 0 0
Padova
Country [54] 0 0
Italy
State/province [54] 0 0
Roma
Country [55] 0 0
Japan
State/province [55] 0 0
Aichi, Seto
Country [56] 0 0
Japan
State/province [56] 0 0
Fukui, Yoshida-gun
Country [57] 0 0
Japan
State/province [57] 0 0
Osaka, Sakai
Country [58] 0 0
Japan
State/province [58] 0 0
Shizuoka, Hamamatsu
Country [59] 0 0
Japan
State/province [59] 0 0
Tokushima, Tokushima
Country [60] 0 0
Japan
State/province [60] 0 0
Tokyo, Mitaka
Country [61] 0 0
Japan
State/province [61] 0 0
Tokyo, Ota-ku
Country [62] 0 0
Japan
State/province [62] 0 0
Tokyo, Shinjuku-ku
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Busan
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Seoul
Country [65] 0 0
Malaysia
State/province [65] 0 0
Kajang
Country [66] 0 0
Malaysia
State/province [66] 0 0
Kuala Lumpur
Country [67] 0 0
New Zealand
State/province [67] 0 0
Papatoetoe
Country [68] 0 0
Poland
State/province [68] 0 0
Bialystok
Country [69] 0 0
Poland
State/province [69] 0 0
Lodz
Country [70] 0 0
Poland
State/province [70] 0 0
Poznan
Country [71] 0 0
Poland
State/province [71] 0 0
Swidnik
Country [72] 0 0
Poland
State/province [72] 0 0
Warsaw
Country [73] 0 0
Poland
State/province [73] 0 0
Warszawa
Country [74] 0 0
Spain
State/province [74] 0 0
Barcelona
Country [75] 0 0
Spain
State/province [75] 0 0
L'Hospitalet de Llobregat
Country [76] 0 0
Spain
State/province [76] 0 0
Madrid
Country [77] 0 0
Spain
State/province [77] 0 0
Oviedo
Country [78] 0 0
Spain
State/province [78] 0 0
Santander
Country [79] 0 0
Spain
State/province [79] 0 0
Sevilla
Country [80] 0 0
Taiwan
State/province [80] 0 0
Kaohsiung
Country [81] 0 0
Taiwan
State/province [81] 0 0
Taichung
Country [82] 0 0
Taiwan
State/province [82] 0 0
Taipei
Country [83] 0 0
Taiwan
State/province [83] 0 0
TaoYuan
Country [84] 0 0
Thailand
State/province [84] 0 0
Bangkok
Country [85] 0 0
Thailand
State/province [85] 0 0
Hat Yai
Country [86] 0 0
Thailand
State/province [86] 0 0
Khon Kaen
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Birmingham
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Cottingham, Hull
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Exeter
Country [90] 0 0
United Kingdom
State/province [90] 0 0
Lancaster
Country [91] 0 0
United Kingdom
State/province [91] 0 0
Leeds
Country [92] 0 0
United Kingdom
State/province [92] 0 0
Manchester
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Oxford
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Boehringer Ingelheim
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Boehringer Ingelheim
Address 0 0
Country 0 0
Phone 0 0
1-800-243-0127
Fax 0 0
Email 0 0
clintriage.rdg@boehringer-ingelheim.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
When will data be available (start and end dates)?
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Available to whom?
For study documents - upon signing of a 'Document Sharing Agreement'.

For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://www.mystudywindow.com/msw/datasharing


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06335303